OXB Oxford Biomedica Plc

TIDMOXB

RNS Number : 2185A

Oxford Biomedica PLC

18 December 2014

Oxford BioMedica plc Director's Share Purchase

Oxford, UK - 18 December 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy company, was informed that on 18 December 2014 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

 
                                                               Interest after purchase 
Director /        Title        Price per   Number of Ordinary  Number of    % of total 
    PDMR                        share (p)    Shares acquired    Ordinary    issued share 
                                                   on            Shares       capital 
                                            25 November 2014 
             Chief Financial 
 Tim Watts        Officer         5.2p          300,000        5,607,829       0.22% 
 

The issued share capital of the Company is 2,565,896,766 1p ordinary shares.

-Ends-

 
 For further information, please contact: 
 
   Oxford BioMedica plc: 
   John Dawson, Chief Executive Officer                 Tel: +44 (0)1865 
   Tim Watts, Chief Financial Officer                   783 000 
 
   Media Enquiries: 
   Mary-Jane Elliott/Chris Welsh/Matthew Neal/Laura     Tel: +44 (0)20 
   Thornton                                             7309 5700 
   Consilium Strategic Communications 
 

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector(R) IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Company has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBSBDDXSBBGSI

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024